Erlotinib customization based on epidermal growth factor receptor (EGFR) mutations in stage IV non-small-cell lung cancer (NSCLC) patients (p)

被引：3
|
作者：
Porta, R.
Queralt, C.
Cardenal, F.
Mayo, C.
Provencio, M.
Camps, C.
Isla, D.
Gonzalez-Larriba, J.
Taron, M.
Rosell, R.
机构：
[1] Girona Hosp Josep Trueta, Girona, Spain
[2] Hosp Badalona Germans Trias & Pujol, Badalona, Spain
[3] Hosp Duran & Reynals, Lhospitalet De Llobregat, Spain
[4] Hosp Univ Puerta del Hierro, Madrid, Spain
[5] Univ Valencia, Gen Hosp, Valencia, Spain
[6] Univ Lozano Blesa, Hosp Clin, Zaragoza, Spain
[7] Univ San Carlos, Hosp Clin, Madrid, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.8038
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8038
引用
收藏
页数：1
相关论文
共 50 条
  • [1] First-line erlotinib in stage IV non-small-cell lung cancer (NSCLC) patients (P) with mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR)
    Massuti, Bartomeu
    Reguart, Noemi
    Vivanco, Guillermo Lopez
    Provencio, Mariano
    Isla, Dolores
    Camps, Carlos
    Ares, Luis Paz
    Pradas, Anna
    Taron, Miquel
    Rosell, Rafael
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 216 - 216
  • [2] Multicenter prospective study of erlotinib in advanced non-small-cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations
    Cardenal, Felipe
    Moran, Teresa
    Queralt, Cristina
    Porta, Ruth
    Camps, Carlos
    Majem, Margarita
    Lopez-Vivanco, Guillermo
    Isla, Dolores
    Provencio, Mariano
    Sanchez, Jose Javier
    Taron, Miquel
    Rosell, Rafael
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S324 - S325
  • [3] Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC)
    O'Leary, Connor
    Gasper, Harry
    Sahin, Katherine B.
    Tang, Ming
    Kulasinghe, Arutha
    Adams, Mark N.
    Richard, Derek J.
    O'Byrne, Ken J.
    [J]. PHARMACEUTICALS, 2020, 13 (10) : 1 - 16
  • [4] Deciding on second- or third-line erlotinib in stage IV non-small-cell lung cancer (NSCLC) patients (P) based on the presence of mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR)
    Porta, Rut
    Terrasa, Josefa
    Rolfo, Cristian
    Gonzalez Larriba, Jose Luis
    Garcia Campelo, Rosario
    Mesia, Carlos
    Pallares, Cinta
    Lianes, Pilar
    Queralt, Cristina
    Rosell, Rafael
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 215 - 216
  • [5] Clinical Outcomes in Patients with Non-Small-Cell Lung Cancer (NSCLC) Harboring Rare Epidermal Growth Factor Receptor (EGFR) Mutations
    Domingues, Pedro M.
    Montella, Tatiane
    Zukin, Mauro
    Baldotto, Clarissa
    Ferreira, Carlos
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S206 - S207
  • [6] Intercalated chemotherapy and erlotinib for non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations
    Zwitter, Matjaz
    Rajer, Mirjana
    Stanic, Karmen
    Vrankar, Martina
    Doma, Andrej
    Cuderman, Anka
    Grmek, Marko
    Kern, Izidor
    Kovac, Viljem
    [J]. CANCER BIOLOGY & THERAPY, 2016, 17 (08) : 833 - 839
  • [7] CUSTOMIZING ERLOTINIB IN METASTATIC NON-SMALL-CELL LUNG CANCER (NSCLC) PATIENTS (P) HARBORING EGFR MUTATIONS
    Sirera, R.
    Catot, S.
    Gonzalez-Larriba, J. L.
    Bover, I.
    Alonso, G.
    Valdivia, J.
    Ibeas, R.
    Lianes, P.
    Martinez del Prado, P.
    Rosell, R.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 : 90 - 90
  • [8] Mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR) and response to first-line erlotinib in advanced non-small-cell lung cancer (NSCLC) patients (p)
    Reguart-Aransay, Noemi
    Mayo, Clara
    Queralt, Cristina
    Botia, Monica
    Pastor, Carmen
    Perez, Maria
    Catot, Silvia
    Prada, Anna
    Galvez, Marc
    Taron, Miquel
    Rosell, Rafael
    [J]. CANCER RESEARCH, 2006, 66 (08)
  • [9] CLINICAL OUTCOMES IN ERLOTINIB-TREATED PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) HARBORING VERY RARE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATIONS
    Domingues, Pedro Masson
    Montella, Tatiane
    Baldotto, Clarissa Serodio
    Siqueira, Mariana
    Zukin, Mauro
    Ferreira, Carlos Gil
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (09) : S169 - S169
  • [10] First-line erlotinib in stage IV non-small cell lung cancer (NSCLC) patients (pts) with mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR)
    Massuti, B.
    Porta, R.
    Paz-Ares, L.
    Cardenal, F.
    Lopez-Vivanco, G.
    Provencio, M.
    Isla, D.
    Pradas, A.
    Taron, M.
    Rosell, R.
    [J]. LUNG CANCER, 2006, 52 : S25 - S26
12345